{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:09:07Z","timestamp":1792786147365,"version":"4.5.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA","id":[{"id":"https:\/\/ror.org\/02891sr49","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To assess the efficacy of prior 9-valent human papillomavirus (9vHPV) vaccination on risk of subsequent cervical, vaginal, and vulvar disease after a cervical excisional procedure for cervical squamous intraepithelial lesion (SIL) in a retrospective clinical trial analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Women aged 16\u201326 years were randomized to three-dose regimens of 9vHPV vaccine, quadrivalent HPV (4vHPV) vaccine, or placebo in three double-blind efficacy trials: a study of 9vHPV vaccine compared with 4vHPV vaccine (ClinicalTrials.gov, NCT00543543) and two historic placebo-controlled 4vHPV vaccine studies (ClinicalTrials.gov, NCT00092521 and NCT00092534). Incidence of subsequent condyloma, cervical, vulvar, or vaginal SIL was compared between 9vHPV vaccine and controls in women who underwent cervical excisional surgery after vaccination and had 6 months or more of follow-up after surgery. For HPV31\/33\/45\/52\/58\u2013related endpoints, the control group was 4vHPV vaccine (from 9vHPV vaccine trial); for HPV6\/11\/16\/18 analysis, the control group was historic placebo (from 4vHPV vaccine trials).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>This analysis included 295 9vHPV vaccine, 722 4vHPV vaccine, and 493 historic placebo recipients who underwent cervical surgery after a median of 1.7 years (range 0.1\u20134.4 years) after dose 1. Subsequent to surgery, HPV6\/11\/16\/18\u2013related SIL incidence was reduced by 95.4% (95% CI, 74.7\u201399.8%) with prior 9vHPV vaccine relative to historic placebo (1.3 vs 29.0\/1,000 person-years, respectively); HPV31\/33\/45\/52\/58\u2013related SIL incidence was reduced by 86.3% (95% CI, 47.5\u201397.8%) with 9vHPV vaccine compared with 4vHPV vaccine (2.7 vs 19.4\/1,000 person-years, respectively). The incidence of high-grade SIL was numerically lower in the 9vHPV vaccine group relative to control, but this was not statistically significant (HPV6\/11\/16\/18 related 69.6% reduction [95% CI, \u2212133.5% to 98.7%]; HPV31\/33\/45\/52\/58 related 82.7% [95% CI, \u221229.2% to 99.2%]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Among female trial participants who underwent cervical excisional surgery, prior vaccination with 9vHPV vaccine (ie, 0.1\u20134.4 years before surgery) reduced the incidence of subsequent cervical and lower genital tract dysplasia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT00543543, NCT00092521, NCT00092534.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000006113","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:00:58Z","timestamp":1761858058000},"page":"73-82","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Effect of Prior 9-Valent Human Papillomavirus Vaccination on Subsequent Lower Genital Tract Dysplasia After Cervical Excisional Surgery"],"prefix":"10.1097","volume":"147","author":[{"given":"Elmar","family":"Joura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne K.","family":"Kjaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Luxembourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Saah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"R1-20260930","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors","volume":"24","author":"Perkins","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"R3-20260930","doi-asserted-by":"crossref","first-page":"e1003665","DOI":"10.1371\/journal.pmed.1003665","article-title":"Cervical intraepithelial neoplasia and the risk of spontaneous preterm birth: a Dutch population-based cohort study with 45,259 pregnancy outcomes","volume":"18","author":"Loopik","year":"2021","journal-title":"PLoS Med"},{"key":"R4-20260930","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejogrb.2019.02.025","article-title":"Obstetric outcomes in patients who have undergone excisional treatment for high-grade cervical squamous intra-epithelial neoplasia","volume":"236","author":"Maina","year":"2019","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R5-20260930","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12916-022-02276-6","article-title":"Associations between cervical intraepithelial neoplasia during pregnancy, previous excisional treatment, cone-length and preterm delivery: a register-based study from western Sweden","volume":"20","author":"Wiik","year":"2022","journal-title":"BMC Med"},{"key":"R6-20260930","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/vaccines11040804","article-title":"The burden of cervical conization in privately insured young and mid-adult women in the United States","volume":"11","author":"Saxena","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"R7-20260930","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.annonc.2019.11.004","article-title":"Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature","volume":"31","author":"Kalliala","year":"2020","journal-title":"Ann Oncol"},{"key":"R8-20260930","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/14760584.2017.1383158","article-title":"9-valent human papillomavirus vaccine: a review of the clinical development program","volume":"16","author":"Luxembourg","year":"2017","journal-title":"Expert Rev Vaccin"},{"key":"R9-20260930","doi-asserted-by":"crossref","first-page":"pky045","DOI":"10.1093\/jncics\/pky045","article-title":"Burden of human papillomavirus (HPV)-related cancers attributable to HPVs 6\/11\/16\/18\/31\/33\/45\/52 and 58","volume":"2","author":"de Sanjos\u00e9","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"R10-20260930","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/1055-9965.EPI-14-0410","article-title":"Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease","volume":"23","author":"Joura","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R11-20260930","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J Infect Dis"},{"key":"R12-20260930","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.rmed.2017.03.030","article-title":"Recurrent respiratory papillomatosis: a state-of-the-art review","volume":"126","author":"Fortes","year":"2017","journal-title":"Respir Med"},{"key":"R13-20260930","doi-asserted-by":"crossref","first-page":"c3493","DOI":"10.1136\/bmj.c3493","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial","volume":"341","author":"Dillner","year":"2010","journal-title":"BMJ"},{"key":"R14-20260930","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet"},{"key":"R15-20260930","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","article-title":"A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions","volume":"2","author":"Kjaer","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"key":"R16-20260930","doi-asserted-by":"crossref","first-page":"e1401","DOI":"10.1136\/bmj.e1401","article-title":"Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data","volume":"344","author":"Joura","year":"2012","journal-title":"BMJ"},{"key":"R17-20260930","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens\u2014part B: biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol"},{"key":"R18-20260930","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Mu\u00f1oz","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"R19-20260930","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ygyno.2019.03.253","article-title":"Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population","volume":"154","author":"Giuliano","year":"2019","journal-title":"Gynecol Oncol"},{"key":"R20-20260930","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/1740774514552110","article-title":"A seamless phase IIB\/III adaptive outcome trial: design rationale and implementation challenges","volume":"12","author":"Chen","year":"2015","journal-title":"Clin Trials"},{"key":"R21-20260930","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1002\/ijc.30391","article-title":"Prior human papillomavirus-16\/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: post-hoc analysis from a randomized controlled trial","volume":"139","author":"Garland","year":"2016","journal-title":"Int J Cancer"},{"key":"R22-20260930","doi-asserted-by":"crossref","first-page":"6194","DOI":"10.1016\/j.vaccine.2023.08.047","article-title":"Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer","volume":"41","author":"Reuschenbach","year":"2023","journal-title":"Vaccine"},{"key":"R23-20260930","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ijgc-2020-001197","article-title":"Prophylactic human papillomavirus vaccination to prevent recurrence of cervical intraepithelial neoplasia: a meta-analysis","volume":"30","author":"Bartels","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"R24-20260930","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/vaccines9050410","article-title":"Adjuvant HPV vaccination to prevent recurrent cervical dysplasia after surgical treatment: a meta-analysis","volume":"9","author":"Di Donato","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"R25-20260930","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/aogs.14359","article-title":"Human papillomavirus vaccination in women undergoing excisional treatment for cervical intraepithelial neoplasia and subsequent risk of recurrence: a systematic review and meta-analysis","volume":"101","author":"Eriksen","year":"2022","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R26-20260930","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.3390\/vaccines10091543","article-title":"Human papillomavirus vaccine impact and effectiveness in six high-risk populations: a systematic literature review","volume":"10","author":"Goodman","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"R27-20260930","doi-asserted-by":"crossref","first-page":"6402","DOI":"10.1016\/j.vaccine.2020.07.055","article-title":"Prophylactic HPV vaccination after conization: a systematic review and meta-analysis","volume":"38","author":"Jentschke","year":"2020","journal-title":"Vaccine"},{"key":"R28-20260930","doi-asserted-by":"crossref","first-page":"e070135","DOI":"10.1136\/bmj-2022-070135","article-title":"Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis","volume":"378","author":"Kechagias","year":"2022","journal-title":"BMJ"},{"key":"R29-20260930","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/AOG.0000000000003833","article-title":"Adjuvant human papillomavirus vaccine to reduce recurrent cervical dysplasia in unvaccinated women: a systematic review and meta-analysis","volume":"135","author":"Lichter","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R30-20260930","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejogrb.2021.11.008","article-title":"If prophylactic HPV vaccination is considered in a woman with CIN2+, what is the value and should it be given before or after the surgical treatment?","volume":"269","author":"Tjalma","year":"2022","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R31-20260930","doi-asserted-by":"crossref","first-page":"2343552","DOI":"10.1080\/21645515.2024.2343552","article-title":"Reduced risk of CIN2+ recurrence in women immunized with a 9-valent HPV vaccine post-excision: retrospective cohort study","volume":"20","author":"Dvo\u0159\u00e1k","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"R32-20260930","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3390\/vaccines10060887","article-title":"HPV vaccination in women with cervical intraepithelial neoplasia undergoing excisional treatment: insights into unsolved questions","volume":"10","author":"Henere","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"R33-20260930","doi-asserted-by":"crossref","first-page":"101337","DOI":"10.1016\/j.lanepe.2025.101337","article-title":"Early and long-term effects of prophylactic and post-excision human papillomavirus vaccination on recurrent high-grade cervical intraepithelial neoplasia relative to margin status: a retrospective cohort study in the Czech Republic","volume":"55","author":"Petr\u00e1\u0161","year":"2025","journal-title":"Lancet Regional Health Europe"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:00:44Z","timestamp":1790780444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000006113","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"2025-05-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}